Company / Return on Equity (ROE)
Ginkgo Bioworks Holdings, Inc. Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-61.5%
FY2025
5-year range
-121.6% / -61.5%
FY2021-FY2025
Trend
+19.5%
vs FY2024
Sector context
#149 of 190
Health Care
What the data says
Ginkgo Bioworks Holdings, Inc. reports negative total equity of -61.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-61.5% in FY2025 with a 5-year CAGR of -34.6%.
Improved from -81.4% to -61.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +59.7pp
- 5-Year Change
- -34.6pp
- 10-Year Change
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 190This company -61.5% Sector average -50.3%
▼
-22.2% below sector average
Key checks
Key Insights
- Ginkgo Bioworks Holdings, Inc.'s return on equity (roe) has grown for 4 consecutive years.
- In FY2025, return on equity (roe) increased 19.5% year-over-year.
- Currently 11.2pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -61.5% | +19.5% |
| FY2024 | -76.4% | +6.1% |
| FY2023 | -81.4% | +32.9% |
| FY2022 | -121.2% | +0.3% |
| FY2021 | -121.6% | -351.3% |
| FY2020 | -26.9% | -13.3% |
| FY2019 | -23.8% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026